Treatment of mild-to-moderate hypertension with calcium channel blockers: a multicentre comparison of once-daily nifedipine GITS with once-daily amlodipine

Kes S., Caglar N., Canberk A., Deger N., Demirtas M., Dortlemez H., ...More

CURRENT MEDICAL RESEARCH AND OPINION, vol.19, no.3, pp.226-237, 2003 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 19 Issue: 3
  • Publication Date: 2003
  • Doi Number: 10.1185/030079903125001677
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.226-237
  • Keywords: amlodipine, antihypertensive agents, calcium channel blockers, clinical trials, GITS, hypertension, essential, nifedipine, CORONARY-ARTERY DISEASE, QUALITY-OF-LIFE, ANTAGONISTS, DILTIAZEM, PHARMACOKINETICS, TOLERABILITY, PERSISTENCE, EFFICACY, TRIAL
  • Gazi University Affiliated: No


Background: Hypertension is one of the most important causes of cardiovascular disease, and treatment of hypertension leads to a significant reduction in cardiovascular mortality and morbidity. Although calcium channel blockers are regarded as an important part of the therapeutic armamentarium against cardiovascular diseases, and are among the most frequently prescribed anti hypertensive medications, concern has been aroused about these drugs, particularly the short-acting dihydropyridine derivatives. However, the value of nifedipine GITS (Adalat-Crono*), the long-acting dihydropyridine, is in need of being re-established.